Jakafi 15 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FHDA7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,749
Award facts
- Contract value 100% obligated
- $37,748.85 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $37,748.85 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 15 mg tablets (60-count units). This firm fixed-price delivery order, awarded on January 21, 2026, with an ultimate completion date of January 22, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order will be fulfilled from DMS Pharmaceutical Group's Park Ridge facility and represents one of numerous delivery orders the company has received under its broader pharmaceutical supply agreement with the Defense Logistics Agency.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, was awarded to DMS Pharmaceutical Group on November 13, 2025, and is structured with a 30-month base period followed by three 30-month option periods. Through this vehicle, the company serves as a critical pharmaceutical supplier for Department of Defense healthcare operations, providing branded and generic prescription drugs, biologics, and medical consumables to support military medical systems globally.
Quick answers
Who was awarded contract SPE2DR26FHDA7?
SPE2DR26FHDA7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FHDA7 worth?
The government has obligated $37,749 on SPE2DR26FHDA7.
Is contract SPE2DR26FHDA7 an order under another contract?
Yes. SPE2DR26FHDA7 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHDA7 competed?
The extent of competition for SPE2DR26FHDA7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award